Alfred Health leads AI trial for epilepsy treatment

Two groups are monitored for 12 months, with findings used to refine the AI model.

Australia’s Alfred Health is the lead site for PERSONAL, a clinical trial evaluating the use of artificial intelligence (AI) in prescribing epilepsy medication.

The trial will monitor two groups for 12 months, with findings used to refine the AI model and enhance its accuracy in epilepsy treatment.

One group’s doctor receives support from the model when prescribing medication, whilst the other prescribes without AI assistance. Participants are unaware of their group allocation.